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Abstract
Aim: Using conventional and novel cardiac magnetic resonance 
(CMR) techniques, we examined cardiac function in a cohort of 
late cancer survivors, previously studied with echocardiography in 
childhood. We compared to healthy controls, to characterize current 
state in the context of longitudinal functional data.
Methods: 30 patients treated with anthracyclines in childhood 
and 19 matched controls underwent echocardiography and CMR. 
Additionally, CMR myocardial T1 maps were obtained using a 
Modified Look-Locker Inversion Recovery (MOLLI) sequence, and 
CMR tissue phase mapping (TPM) was performed using a rotating 
golden-angle spiral acquisition.
Results: Patients were a median (range) age 33 (25-43) years, and 
were studied 27(16-33) years following a cumulative anthracycline 
dose of 220 (90-370) mg/m2. Mean extracellular volume fraction 
(ECV) in patients was 0.26 ± 0.04, and was higher in patients receiving 
cumulative doses of >300mg/m2 (0.25 ± 0.02 vs. 0.28 ± 0.05, p=0.02). 
Native myocardial T1 was similar between patients and controls (967 
± 37 vs. 960 ± 37, p=0.53). TPM-derived LV radial and longitudinal 
systolic velocities, and longitudinal E:A ratio were not significantly 
reduced. Current CMR-derived LV ejection fraction was normal, 
although reduced compared to controls (61% ± 6 vs. 65% ± 5, p<0.01). 
This correlated negatively with cumulative anthracycline dose (R2 
0.26, p<0.01) and positively with historic echo fractional shortening 
(R2 0.27, p <0.03).
Conclusion: This detailed CMR assessment of a cohort of 
survivors, 25 years following childhood anthracycline chemotherapy, 
showed persistent impairment, but often sub-clinical and dose-
dependent. Novel CMR myocardial characterization and motion 
analysis found no differences compared to controls, but with greater 
numbers, these techniques may provide insight into long-term features 
of myocardial damage and remodeling.
Keywords: Anthracycline; Cardiotoxicity; Magnetic resonance 
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Background
Progressive advances in treatment strategies for childhood cancer 
have resulted in great improvements in survival, with overall 5-year 
survival almost 80% [1]. However, cardiovascular complications are a 
leading cause of morbidity and mortality in long-term survivors [2].
Compared to the general population, survivors of childhood cancer 
are at an increased risk of developing congestive cardiac failure, and 
are at increased risk of premature death due to cardiac causes [2]. 
There is a strong, dose-dependent relationship between anthracycline 
chemotherapy and risk of congestive cardiac failure, which is further 
increased by exposure to chest radiation. 
In survivors of childhood cancer, there is often a long latency 
period between the cardiotoxic exposure to anthracyclines and clinically 
evident disease. North American and European groups have recently 
harmonized clinical practice guidelines for monitoring survivors of 
childhood cancer [3]. Among many recommendations from this group, 
is advice for long-term echocardiographic surveillance, in the first 
instance [4]. However, echocardiography is less sensitive than cardiac 
MRI when detecting sub-clinical myocardial abnormality [5]. Detecting 
subtle abnormality and predicting ongoing risk of dysfunction is crucial 
to rational surveillance, because early medical therapy to ameliorate 
loading, may alter progression.
Cardiovascular magnetic resonance is the reference standard for 
assessment of ventricular volume, myocardial mass and systolic function, 
but also has proven utility in the detection of subtle abnormalities of 
myocardial structure and motion. 
Post mortem studies of the explanted hearts of patients transplanted 
for anthracycline-induced cardiomyopathy describe myocyte loss with 
diffuse replacement fibrosis [6]. CMR uses gadolinium-based contrast, 
and because this contrast remains extracellular, the resulting expansion 
in extracellular space can be both detected and quantified by CMR. 
The derived extracellular volume fraction (ECV) has been shown to 
correlate with diffuse myocardial fibrosis in histological specimens [7]. 
The extracellular volume has been shown to be elevated in adult patients 
treated with anthracyclines, seven years after therapy [8]. The work of 
Tham et al in older children showed ECV to correlate with cumulative 
anthracycline dose 8 years after completion of therapy [9]. However, 
to our knowledge, no CMR study has examined the functional and 
tissue characteristics of the ventricular myocardium in childhood cancer 
survivors beyond these earlier and middle-range periods.
Novel CMR techniques are being developed, with the ability 
to quantify both global and regional myocardial motion. Tissue 
phase mapping (TPM) allows assessment of the separate directional 
components of myocardial wall motion, as well as their regional 
distribution, with high spatial resolution [10]. By determining peak 
systolic and diastolic myocardial velocities in three planes, (radial, 
tangential and longitudinal) TPM enables quantification of both systolic 
and diastolic function, globally and regionally.
Combining conventional and novel CMR techniques, the aim 
of this study was to examine a cohort of late cancer survivors who 
had all previously been studied with echocardiography in childhood, 
in our institution. We hoped to acquire crucial longitudinal data in 
these patients, and at the same time assess the feasibility of CMR to 
characterize both subtle and overt current myocardial abnormalities, in 
comparison to healthy, aged-matched control subjects. 
Methods
Study design
This was a cross-sectional, observational study. However, patients 
were recruited from cohorts of previously-studied patients, and historical 
data allowed longitudinal comparisons.
Copyright © 2017 The Authors. Published by Scientific Open Access 
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Study population
Eligible patients were recruited from databases of three previous 
research studies at our institution, Great Ormond Street Hospital for 
Children, in London UK [11,12]. These previous studies had utilized 
transthoracic echocardiography (TTE) in most patients, to describe 
the early cardiac effects of anthracycline chemotherapy in paediatric 
patients with acute lymphoblastic leukaemia (ALL), acute myeloid 
leukaemia (AML) and Wilms tumour (WT). 
Patients from these studies, who remained under the care of the 
Oncology Late Effects team within our linked, adult institution, were 
contacted through their oncologist and invited to participate in our 
study.
Patients who had received a cardiac transplant following 
anthracycline treatment or who had concomitant congenital heart 
disease were excluded. Patients with standard contraindications to 
CMR (e.g. metallic devices, claustrophobia) were also excluded.
Ethics
The study was approved by the Great Ormond Street Hospital 
research Ethics Committee. All patients had normal renal function, 
and the use of gadolinium contrast agent was considered to be low 
risk. Written, informed consent was obtained from all individual 
participants included in the study.
Echocardiography
Transthoracic echocardiography was performed using a Philips 
IE33 echocardiography system (Philips Healthcare, Best, Netherlands). 
Conventional systolic functional parameters were measured. These 
included: ejection fraction (EF) by Simpson’s biplane method, and 
fractional shortening (FS) measured in the parasternal long axis view. 
Trans-mitral inflow velocities were acquired using pulsed-wave 
Doppler with the sample volume placed at the tip of the mitral valve 
leaflets in the apical 4-chamber view. The peak E-wave velocity 
(cm/s), peak A-wave velocity (cm/s), and ratio of E-wave to A-wave 
(E:A) velocities were recorded.
Tissue Doppler Imaging (TDI) myocardial velocities were 
measured using a standard pulsed-wave Doppler technique. Images 
were acquired over two consecutive cardiac cycles using low-velocity, 
high-intensity myocardial signals at a high frame rate (>120 MHz). 
The sample volume was placed at the junction of the LV wall with 
the mitral annulus at the septal and lateral myocardial segments in the 
apical 4-chamber view. Peak E’ velocities (cm/s) were measured on-
line and corresponding E:E’ ratios were calculated.
Cardiac magnetic resonance
All CMR imaging was performed on a 1.5-T MR Scanner (Avanto, 
Siemens, Erlangen, Germany). A 12-element phased-array coil was 
used for signal reception and a vectorcardiogram system was used for 
cardiac gating. 
Retrospective-gated steady-state free precession cine images of the 
heart were acquired in the vertical long axis and the 4-chamber view. 
Biventricular volumetric and functional assessment was performed 
using 10-13 contiguous short-axis cine images, covering the entirety 
of both ventricles. 
Each individual image slice was acquired during a single breath-
hold. Image variables were: repetition time 2.4ms, echo time 1.2ms, 
flip angle 68 degrees, slice thickness 10mm, matrix 200x240, field of 
view 350-400mm, and temporal resolution optimized to achieve 20 
true phases. 
Through-plane pulmonary artery and aortic valve flow data was 
acquired using a spiral triggered flow sequence during breath-hold [13].
Myocardial T1 mapping was performed using a modified Look-
Locker Inversion Recovery (MOLLI) sequence [14]. Images were 
captured in the standard mid-cavity short axis and long axis 4 chamber 
views in diastole, both pre-contrast (native T1) and 15 minutes post 
contrast injection. Scan parameters for the MOLLI protocol were: FOV, 
8mm slice thickness, flip angle 30, T1 100ms.
Gadopentetate dimeglumine (Gd-DTPA; Magnevist; Schering, 
Berlin, Germany) was administered at a dose of 0.15 mmol per 1 kg 
body weight at an injection rate of 2ml/s followed by a 10ml saline 
flush. 
Late gadolinium-enhanced images were acquired 5 minutes 
after intravenous injection of contrast. TI was calculated to null the 
myocardium. 
Hematocrit was measured at the time of CMR, by taking a blood 
sample at the time of peripheral intravenous access for contrast 
administration. 
Tissue phase mapping
CMR tissue phase mapping (TPM) was performed using a 
respiratory self-navigated, rotating golden angle spiral acquisition with 
retrospective cardiac gating [10]. A single acquisition was performed at 
the mid-ventricular position in the short axis orientation.
Cardiac MR image analysis
All images were processed using in-house plug-ins for the open-
source DICOM software OsiriX (OsiriX Foundation, Geneva, 
Switzerland) [15].
The biventricular end-diastolic volume (EDV) and end-systolic 
volume (ESV) were measured by manual segmentation of the short 
axis cine images. The endocardial borders were traced at end-diastole 
and end-systole, excluding trabeculations and papillary muscles from 
the blood pool. End-diastolic volume (EDV) and end-systolic volume 
(ESV) were calculated for each ventricle using Simpson’s rule. 
Ventricular stroke volume (SV) was calculated with the difference 
between the EDV and ESV, and ventricular ejection fraction (%) was 
(SV/EDV)×100.
All volume measurements were indexed for the body surface area 
and expressed in mL/m2.
Internal validation of the ventricular stroke volume data was 
attained by quantifying aortic and pulmonary valve forward flow 
volume, using a semi-automatic vessel edge-detection algorithm with 
operator correction.
The late-enhancement images were independently reviewed by 2 
cardiologists (S.Q, M.L.H.) in a blinded fashion.
ECV values were calculated as previously described (*REF 
MOON) using the following formulas: ΔR1myo=1/T1myo-post–1/T1myo-pre; 
ΔR1blood=1/T1blood-post–1/T1blood-pre; and ECV=ΔR1myo/ΔR1blood×(100–
HCT). 
For the TPM data, the endocardial and epicardial myocardial 
borders were manually segmented throughout the cardiac cycle, using 
the modulus images. Following motion correction, the inplane velocities 
were transformed to an internal polar coordinate system, positioned at 
the centre-of-mass of the segmented ventricle. This allowed motion to be 
identified as contraction (radial velocities) and shortening (longitudinal 
velocities) as previously described [16]. 
Colour-coded maps were generated for each velocity component to 
allow easy visualization of the results. Additionally, graphs of regional 
and global myocardial motion patterns over time were calculated, by 
averaging the velocity components within the region of interest. The 
peak velocities in the S (systolic), E (early diastolic), and A (atrial 
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systolic) waves were measured for the longitudinal and radial velocities 
within the entire myocardium 
Statistical analysis
Data are presented as mean ± SD or median (range) as appropriate. 
Normal distribution of data was confirmed using the Shapiro-Wilk test.
Baseline demographic, CMR and echo parameters were compared 
between anthracycline patients and controls. A 2-sided t-test was used 
for normally distributed variables. Kolmogorov-Smirnov test was used 
for skewed data. Fisher’s exact test was used for categorical variables.
All statistical analysis was performed using Stata SE12.
Results
Study population
A total of 30 patients replied to the invitation to participate in this 
study, and were assessed alongside 19 age and sex-matched controls. 
Patient and control group baseline characteristics were not 
significantly different, and are summarized in Table 1.
The patients had a median age 33 (25-43) years. The completion 
of their single anthracycline chemotherapy regimen had been a median 
27 (16-33) years prior to this assessment.
The patients’ oncology diagnosis had been acute lymphocytic 
leukaemia (ALL) in 23 (77%), acute myelocytic leukaemia (AML) in 
2 (7%) and Wilms Tumour (WT) in 5 (17%). They had received a 
median cumulative anthracycline dose of 270mg/m2 (range 90-370mg/
m2). Twenty five patients had received radiotherapy (16 cranial only, 
9 total body or chest and abdominal) with a median dose of 18 (12-48) 
Gy. Seven (23%) patients had undergone bone marrow transplantation 
(BMT).
Five (17%) patients were known to have systolic dysfunction 
(defined as echocardiographic FS <25%) and were being treated 
with angiotensin converting enzyme inhibitors (ACEi), Angiotensin 
receptor blockers (ARB) or beta blockers. 
Echocardiographic parameters
Twenty three patients had historical FS data available from the 
previous studies in our centre. This data had been obtained a median 
of 9 (3-20) years after completing anthracycline therapy. In these 23 
patients, median previous FS was 32% (26-46)%, within the normal 
range. 
In the present study, FS was repeated in patients and acquired in 
controls. The patients’ current median FS was 29% (23-37%). In these 
patients with longitudinal data, the previous echo FS, correlated with 
the current measure (R2 0.27, p <0.03) (Figure 1).
The current echo FS was not significantly different between 
patients and controls. Mean left ventricular internal diameter in 
diastole (LVIDD) was larger in patients (mean 49 ± 6mm) but did not 
differ significantly from controls. 
Echo-derived mitral inflow velocities were normal and did not 
differ between patient and control groups. Peak E velocity was 0.85 ± 
0.1 vs. 0.9 ± 0.1 p=0.39 and Peak A velocity was 0.53 ± 0.6 vs. 0.52 ± 
0.1 with normal E:A (1.7 ± 0.3 vs. 1.7 ± 0.4 p=0.95). 
Tissue Doppler imaging showed significantly reduced medial E’ 
velocities in patients, but no difference in lateral E prime or medial or 
lateral E:E’. 
Conventional MRI parameters
Data in Table 2 demonstrates that global measures of left 
ventricular systolic function were within established normal range, but 
were significantly lower in patients as compared to controls. This is 
explained by the increased LV end-systolic volume in patients (30 ± 8 
mL/m2 vs 25 ± 6mL/m2, p=0.05).
In line with this, the mitral annular peak systolic excursion, 
measured using CMR long-axis cine images, was decreased in patients 
compared to controls (13 ± 2.6mm vs 15 ± 1.1mm, p=0.02).
LV mass and LV mass index were normal in the cohort, with no 
difference between patients and controls. 
Focal mid-wall late gadolinium enhancement was present in 2 
patients one of whom was known to have LV systolic dysfunction 
treated with ACEi. 
T1 Mapping
Precontrast (“native”) T1 values for the myocardium were obtained 
in control subjects and patients. There was no significant difference in 
the mean myocardial T1 between the groups. 
However, within the patient group, there was higher myocardial 
native T1 found in the patients who had previously received greater 
than 300g/m2 cumulative dose of anthracyclines.
Variable Control (n = 19) Patients (n = 30) P value
Female n (%) 10 (53) 17 (57) 0.86
Current Age (years) 32 (26-39) 32 (23-42) 0.96
Height (cm) 171 ± 6.3 169 ± 9.2 0.30
Weight (kg) 67 ± 8 75 ± 21 0.10
NYHA I / II 19 (100) / 0 (0) 28 (93) / 2 (7) 0.44
Systolic BP (mmHg) 120 ± 10 123 ± 15 0.46
Diastolic BP (mmHg) 73 ± 7 75 ± 11 0.60
AML n (%) - 2 (7) -
ALL n (%) - 23 (77) -
Wilms n (%) - 6 (17) -
Age at diagnosis 
(years) - 4.6 (1-15) -
Time since chemo 
(years) - 27 (16-33) -
Anth Dose (mg/m2) - 270 (90-370) -
Radiotherapy n (%) - 25 (83) -
BMT n (%) - 7 (23) -
* Values expressed as mean ± SD. 
NYHA = New York Heart Association; BP = blood pressure; AML 
= acute myelocytic leukaemia; ALL = acute lymphocytic leukaemia; 
BMT = bone marrow transplant.
Table 1: Baseline patient and control group characteristics*.
Figure 1: Fractional Shortening (%) measured with 
echocardiography; historic compared to current.
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Within the patient group, the mean myocardial extracellular volume 
fraction (ECV) was within a normal reference range (0.26 ± 0.04). 
However, again, the patients who had previously received >300mg/
m2 anthracyclines had significantly higher ECV fraction than patients 
who had received lower doses. ECV fraction was not associated with 
either diastolic functional parameters or regional myocardial systolic 
function.
Tissue phase mapping
Compared with normal subjects, patients tended to show lower 
mean values of peak radial systolic velocities, but this difference was 
not significant. Generally, compared to normal subjects, the graphs 
of regional and global myocardial motion patterns over time showed 
that patients had a greater range of values of peak systolic radial and 
longitudinal velocities, demonstrating greater variability in regional 
wall motion characteristics. (Figure 2) 
There was no difference in the TPM peak systolic radial and 
longitudinal velocities between patients who had received higher or 
lower dose anthracycline therapy.
Discussion
To our knowledge, this is the first study to describe detailed 
myocardial function and tissue characteristics of cancer survivors 
approximately 25 years after therapy, measured with echocardiography 
and CMR. 
Although this cohort of late survivors had a normal mean CMR-
derived LV ejection fraction, our data shows a subtle, asymptomatic 
reduction of LVEF, and a significant effect of higher-dose anthracycline 
regimens. Additionally, the novel CMR measures of myocardial tissue 
characterization demonstrated a significant dose-effect, with increased 
myocardial ECV fraction in patients late after receiving higher 
cumulative doses of anthracycline therapy.
These findings are consistent with the findings of Tham et al. [9] 
who studied patients eight years after childhood anthracycline therapy. 
The risk of developing anthracycline-induced cardiomyopathy has 
previously been shown to be a function of cumulative anthracycline 
dose [17].
Although the mechanisms and pathophysiology of anthracycline-
induced cardiomyopathy remains incompletely resolved, myocyte loss 
by necrosis has been demonstrated and such cell death has also been 
shown in progenitor cell populations [18]. 
Echocardiographic studies have long since shown that myocardial 
mass is decreased in patients long-term after anthracycline therapy, but 
the effect on mass is not evident with echocardiographic imaging until 
late in the process. 
This has led to the postulation that more subtle myocyte loss could be 
demonstrated at an earlier stage, by using CMR tissue characterization 
techniques, including native T1 mapping and measurement of ECV 
fraction. ECV fraction has been suggested as a potential biomarker for 
the early detection of generalized myocyte damage.
Our study did not find a significantly higher mean ECV fraction 
among the whole group of patients compared to previously published 
normal data, but we did find a significant difference in the ECV fraction 
within our patients who had received a high cumulative anthracycline 
dose compared with those who had received lower doses.
Comparison between ECV values from different studies requires 
caution due to inherent differences in CMR sequences and acquisition 
techniques. To our knowledge there have been 3 major studies reporting 
ECV fraction after anthracycline therapy, all of which have focused on 
the period 8-10 years after therapy. Tham et al used the SASHA sequence 
and report and mean ECV fraction of 0.21 ± 0.04 in older children 7 
years after therapy [9]; Neilan et al. used a Lock locker sequence and 
reported higher ECV value of 0.36 ± 0.03 in adult patients 8 years after 
anthracycline therapy [8]; Toro-Salazar et al used a MLLSR sequence 
and found ECV to be normal as compared with controls (0.25 ± 0.01) 
a mean of 10 years after therapy [19]. In all three studies, the patient 
cohorts had received similar median anthracycline doses.
Although measuring the ECV fraction using gadolinium-based 
contrast is a promising CMR technique for assessing increased 
myocardial interstitial space, better standardization of scanning 
protocols between institutions and more robust knowledge of the range 
Variable Control (n =19) Patients (n = 30) p Value
LVEDV index (ml/
m2) 72 ± 8 73 ± 12 0.92
LVESV index (ml/m2) 25 ± 6 30 ± 8 *0.05
LV EF (%) 65 ± 5 61 ± 6 *0.01
LV mass index (g/m2) 60 ± 10 58 ± 11 0.53
RVEDV index (ml/
m2) 76 ± 8 69 ± 12 0.10
RVESV index (ml/m2) 29 ± 6 28 ± 14 0.68
RV EF (%) 62 ± 4 63 ± 5 0.39
MAPSE (cm) 15 ± 1.1 13 ± 2.6 *0.02
Left Atrial Area (cm2) 20 ± 2.3 21 ± 3.1 0.47
Native myocardial T1 960 ± 37 967 ± 37 0.53
Native blood pool T1 1484 ± 76 1463 ± 118 0.50
ECV - 0.26 ± 0.04
LGE - 2 (7)
*Values expressed as mean ± SD. 
LVEDV = left ventricular end diastolic volume; LVESV = left 
ventricular end systolic volume; LVEF = left ventricular ejection 
fraction; RVEDV = right ventricular end diastolic volume; RVESV = 
right ventricular end systolic volume; RVEF = right ventricular ejection 
fraction; MAPSE = mitral annular plane systolic excursion; ECV = 
Extracellular volume fraction; LGE = Late gadolinium enhancement









LVEDV index (ml/m2) 71 ± 11 80 ± 14 0.10
LVESV index (ml/m2) 28 ± 8 36 ± 6 *0.03
LV EF (%) 65 ± 5 54 ± 6 *0.01
LV Mass index (g/m2) 58 ± 11 59 ± 9 0.94
RVEDV index (ml/m2) 70 ± 10 69 ± 17 0.87
RVESV index (ml/m2) 28 ± 15 26 ± 7 0.77
RV EF (%) 63 ± 5 62 ± 2 0.46
MAPSE (cm) 13 ± 2.1 13 ± 4.1 0.72
Left Atrial Area (cm2) 21 ± 3 21 ± 4 0.94
Native T1 960 ± 39 992 ± 24 *0.05
Native blood pool T1 1464 ± 79 1527 ± 38 *0.05
ECV 0.25 ± 0.02 0.28 ± 0.05 *0.02
LGE 1 (14) 1 (5)
*Values expressed as mean ± SD.
MR = magnetic resonance; LVEDV = left ventricular end diastolic 
volume; LVESV = left ventricular end systolic volume; LVEF = left 
ventricular ejection fraction; RVEDV = right ventricular end diastolic 
volume; RVESV = right ventricular end systolic volume; RVEF = 
right ventricular ejection fraction; MAPSE = mitral annular plane 
systolic excursion; ECV = Extracellular volume fraction; LGE = Late 
gadolinium enhancement
Table 3: CMR data comparing patients with high cumulative 
anthracycline dose to patients with lower cumulative anthracycline 
dose*.
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of normal values with established protocols is necessary for this 
technique to have widespread clinical value. 
There is possibly more potential clinical value in characterizing 
myocardial tissue using quantitative T1 mapping without the use of 
contrast; thereby revealing interstitial characteristics without contrast 
risks. Our study showed that the anthracycline group as a whole did 
not demonstrate significantly different myocardial native T1 values, 
however within the anthracycline-treated group, those who had received 
higher doses had increased native myocardial T1 signal. This suggests 
pathological change, which may be an early indicator of subclinical 
cardiomyopathy. In patients with aortic valve stenosis, native T1 values 
correlated with the degree of biopsy-quantified fibrosis [20]. Our study 
showed that this technique is feasible in a clinical setting and could 
be used as a non-invasive, non-contrast assessment of diffuse fibrosis. 
Work is needed to determine more precisely the role in risk stratification 
Figure 2: A graphical representation of Tissue Phase Mapping data from both a patient and a control, including the radial, longitudinal and 
tangential velocities of the mid-left ventricular myocardium over a single cardiac cycle.
 
 
Control (Female 27yrs) 
 
Patient (Female 38yrs)
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or the role in monitoring potential future myocardial protection 
techniques or antifibrotic treatments.
The novel MRI technique of tissue phase mapping (TPM) also shows 
promise as a method for detecting subtle changes in wall motion and 
quantifying these in a regional manner, unhampered by poor acoustic 
windows. Many studies, including that by Armstrong et al [5], have 
shown the suboptimal sensitivity of transthoracic echocardiography in 
detecting subtle changes in ventricular systolic contraction, limiting 
the screening performance of echocardiography. In our study CMR 
TPM showed good feasibility, and suggested important changes in 
the function of anthracycline-exposed myocardium. However, our 
study may have been underpowered to show significant patterns of 
abnormality in patients, compared to controls. In agreement with 
other studies we report a wide variation in individual TPM findings 
in patients, not entirely explained by cumulative anthracycline dose. 
In agreement with others, this finding suggests additional potential 
modulators of the myocyte reponse to anthracycline exposure, which 
are, as yet, incompletely elucidated.
Limitations
This study was designed to explore the feasibility of novel CMR 
markers of subtle myocardial tissue and motion characteristics.
The study cohort was small, and voluntary, from a group of long 
term survivors who remained in follow up at our local adult institution. 
The cohort was also relatively heterogeneous, in terms of their 
original cancer diagnosis, additional radiation therapy and varying 
treatment protocols. All these factors are important likely sources of 
variability for all findings, and may contribute to decreased statistical 
power.
No gadolinium contrast was given to the age-sex matched 
controls in our study, so we were not able to record normal values 
of the post-contrast myocardial T1 map, using the MOLLI sequence 
in our institution. We relied on previously published normal values. 
Although we mimicked the methodology from similar studies, this is 
a rapidly developing field, and image variability contributed by the 
magnet type, the scanning sequence, dosing regimen and timing of 
image acquisition will impair the comparability of the findings to those 
from other centres. 
Conclusions 
This study is one of the first to examine in detail the very long-term 
cardiac effects of anthracycline, in survivors of childhood treatment. 
The study explored conventional and novel, non-invasive and non-
toxic methods of CMR imaging. 
The study showed persistent, often sub-clinical and dose-dependent 
myocardial impairment. Novel CMR myocardial characterization and 
motion analysis was feasible and effective. Although in this small 
cohort, little difference was found compared to controls, improving 
and validating these promising methods may be the best way to further 
unravel the complex mechanisms of myocyte injury, to monitor 
patients and to find means of preventing long-term anthracycline-
related cardiomyopathy in the future.
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